Robles AJ, Kornblith LZ, Hendrickson CM, Howard BM, Conroy AS, Moazed F, Calfee CS, Cohen MJ, CallcutRA.
J Trauma Acute Care Surg. 2018 Jul;85(1):148-154. doi: 10.1097/TA.0000000000001926.
PMID: 29958249
About
Vasomune Therapeutics is a private biotechnology company developing Pegevongitide (AV-001), a first-in-class fully synthetic PEGylated peptide targeting the Tie2 receptor. Activation of the Tie2 receptor by Pegevongitide plays a critical role in improving vascular stability, barrier integrity and endothelial quiescence.